Properties (46)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:awards |
various industry awards
|
| gptkbp:clinicalTrials |
ongoing
completed |
| gptkbp:communityInvolvement |
patient advocacy
healthcare_initiatives |
| gptkbp:employees |
approximately 1,000
|
| gptkbp:financials |
publicly traded
revenue growth investment in R&D |
| gptkbp:focusesOn |
regenerative medicine
|
| gptkbp:founded |
2008
|
| gptkbp:founder |
gptkb:Shire_Pharmaceuticals
|
| gptkbp:globalPresence |
gptkb:Asia
gptkb:North_America Europe |
| gptkbp:headquarters |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Shire Regenerative Medicine
|
| gptkbp:industry |
Biotechnology
|
| gptkbp:innovation |
advanced manufacturing techniques
cutting-edge therapies biologics_development |
| gptkbp:market |
global
|
| gptkbp:mission |
transforming lives through regenerative medicine
|
| gptkbp:parentCompany |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:partnerships |
biopharmaceutical companies
various academic institutions |
| gptkbp:products |
gptkb:Dermagraft
gptkb:Apligraf |
| gptkbp:regulatoryCompliance |
FDA_approved
EMA_approved |
| gptkbp:researchFocus |
wound healing
cell-based therapies chronic wounds |
| gptkbp:services |
tissue engineering
cell therapy |
| gptkbp:sustainabilityPractices |
ethical sourcing
environmental responsibility |
| gptkbp:values |
gptkb:collaboration
innovation integrity excellence patient-centric approach |
| gptkbp:vision |
leading in regenerative therapies
|
| gptkbp:website |
www.shire.com
|